Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression

Journal of Nutritional Biochemistry

Volumn 22, Issue 2, 2011, Pages 164-171

  Hie, Mamiko ^a   Tsukamoto, Ikuyo ^a  

^a NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Extracellular signal regulated kinase; M CSF signaling; Osteoclastogenesis; Receptor activator nuclear factor kappaB; Vitamin C

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ASCORBIC ACID; COLONY STIMULATING FACTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOPROTEGERIN; PROTEIN C FOS; PROTEIN C JUN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTICLE; ASCORBIC ACID DEFICIENCY; BONE MARROW CELL; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; RAT; TIBIA; VITAMIN SUPPLEMENTATION;

ANIMALS; ASCORBIC ACID DEFICIENCY; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FEMALE; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MONOCYTES; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RATS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

RATTUS;

EID: 78651256353     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.01.002     Document Type: Article

References (29)

1. Nishikimi M., Yagi K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am J Clin Nutr 1991, 54:1203S-1208S.
2. Ragab A.A., Lavish S.A., Banks M.A., Goldberg V.M., Greenfield E.M. Osteoclast differentiation requires ascorbic acid. J Bone Miner Res 1998, 13:970-977.
3. Otsuka E., Kato Y., Hirose S., Hagiwara H. Role of ascorbic acid in the osteoclast formation: Induction of osteoclast differentiation factor with formation of the extracellular collagen matrix. Endocrinology 2000, 141:3006-3011.
4. Ganta D., McCarthy M.B., Gronowicz G.A. Ascorbic acid alters collagen integrins in bone culture. Endocrinol 1997, 138:3609-3612.
5. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
6. Lean J.M., Davies J.T., Fuller K., Jagger C., Kirstein B., Partington G.A., et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003, 112:915-923.
7. Goto A., Tsukamoto I. Increase in tartrate-resistant acid phosphatase of bone at the early stage of ascorbic acid deficiency in the ascorbate-requiring Osteogenic Disorder Shionogi (ODS) rat. Calcif Tissue Int 2003, 73:180-185.
8. Mizushima Y., Harauchi T., Yoshizaki T., Makino S. A rat mutant unable to synthesize vitamin C. Experientia 1984, 40:359-361.
9. Konishi T., Makino S., Mizushima Y., Harauchi T., Hasegawa Y., Yoshizaki T., et al. What is the ODS rats? Historical description of the characterization studies. Vitamin C and the scurvy-prone ODS rat 1991, 3-22. Elsevier, Amsterdam, The Netherlands. T. Fujita, M. Fukase, T. Konishi (Eds.).
10. Togari A., Arai M., Nakagawa S., Banno A., Aoki M., Matsumoto S. Alteration of bone status with ascorbic acid deficiency in ODS (Osteogenic Disorder Shionogi) rats. Jpn J Pharmacol 1995, 68:255-361.
11. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
12. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
13. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
14. Udagawa N., Takahashi N., Akatsu T., Tanaka H., Sasaki T., Nishihara T., et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A 1990, 87:7260-7264.
15. Kurihara N., Chenu C., Miller M., Civin C., Roodman G.D. Identification of committed mononuclear precursors for osteoclast-like cells formed in long term human marrow cultures. Endocrinology 1990, 126:2733-2741.
16. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999, 190:1741-1754.
17. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
18. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000, 275:31155-31161.
19. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., et al. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 2000, 148:333-342.
20. David J.P., Sabapathy K., Hoffmann O., Idarraga M.H., Wagner E.F. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation dependent and -independent mechanisms. J Cell Sci 2002, 115:4317-4325.
21. Hie M., Shimono M., Fujii K., Tsukamoto I. Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats. Bone 2007, 41:1045-1050.
22. Hie M., Yamazaki M., Tsukamoto I. Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes. Eur J Pharmacol 2009, 621:1-9.
23. Hayashi S., Miyamoto A., Yamane T., Kataoka H., Ogawa M., Sugawara S., et al. Osteoclast precursors in bone marrow and peritoneal cavity. J Cell Physiol 1997, 170:241-247.
24. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
25. Otsuka E., Yamaguchi A., Hirose S., Hagiwara H. Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid. Am J Physiol 1999, 277:C132-C138.
26. Franceschi R.T., Iyer B.S., Cui Y. Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-E1 cells. J Bone Miner Res 1994, 9:843-854.
27. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000, 191:275-286.
28. Vera J.C., Rivas C.I., Velasquez F.V., Zhang R.H., Concha I.I., Golde D.W. Resolution of the facilitated transport of dehydroascorbic acid from its intracellular accumulation as ascorbic acid. J Biol Chem 1995, 270:23706-23712.
29. Carcamo J.M., Borquez-Ojeda O., Golde D.W. Vitamin C inhibits granulocyte macrophage-colony-stimulating factor-induced signaling pathways. Blood 2002, 99:3205-3212.